Navigation Links
Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting

upplemental oxygen, which increases their risk of developing BPD. Discovery believes that after an initial RDS treatment, BPD may be successfully treated with repeated doses of a non-immunogenic, precision-engineered synthetic surfactant (Surfaxin) to improve the clinical outcome of these infants.

Discovery's Proprietary KL-4 Surfactant Technology: Product Candidates Surfaxin(r) and Aerosurf(tm)

Discovery's surfactant product candidates, including Surfaxin and Aerosurf, are engineered versions of natural human lung surfactant and contain the precision-engineered KL-4 peptide. KL-4 is a 21 amino acid protein-like substance that is designed to closely mimic the essential attributes of human surfactant protein B (SP-B), the surfactant protein most important for the proper functioning of the respiratory system. KL-4 surfactant has the potential to be precisely formulated, either as a liquid instillate, aerosolized liquid or dry powder, to address various respiratory diseases affecting premature infants, children and adults.

Surfaxin, a precision-engineered Surfactant Replacement Therapy (SRT) administered as a liquid-instillate, represents a potential alternative to animal-derived surfactants. Surfaxin's precision-engineered and non-immunogenic nature allows it to be further developed as a therapeutic to address other pulmonary conditions in neonatal and pediatric medicine. Data from Discovery's pivotal, multinational SELECT study demonstrate that Surfaxin is significantly more effective in the prevention of RDS and results in improved survival (continuing through at least one year of life) and other outcomes versus comparator surfactants. The SELECT and STAR (a supportive Phase 3 study) trials, as well as a pooled Phase 3 analysis, have been presented at several international medical meetings and the results from the two studies were published in Pediatrics.

Aerosurf is a precision-engineered, aerosolized SRT administered via nasal continuou
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
3. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:7/29/2015)... -- RXi Pharmaceuticals Corporation (NASDAQ: RXII ), a biotechnology ... in the areas of dermatology and ophthalmology today announced ... quarter ended June 30, 2015 on Wednesday, August 12, ... A live audio webcast will begin ... under the "Investors" section of the Company,s website, ...
(Date:7/29/2015)... July 29, 2015   BioLife Solutions , Inc. ... marketer of proprietary clinical grade hypothermic storage ... thermal shipping products for cells and tissues  ("BioLife" ... quarter 2015 financial results will be released on Thursday, ... a conference call and live webcast at 1:30 p.m. ...
(Date:7/29/2015)... Legal-Bay LLC, The Lawsuit Settlement Funding Company, announced today that ... District of West Virginia (W.Va) pushed ... to start in November. The first trial that was set ... and now it involves 39 women, and the trial has ... an article in Reuters. The alterations were made after data ...
Breaking Medicine Technology:RXi Pharmaceuticals to Webcast Second Quarter 2015 Financial Results on Wednesday, August 12, 2015 2RXi Pharmaceuticals to Webcast Second Quarter 2015 Financial Results on Wednesday, August 12, 2015 3BioLife Solutions to Report Second Quarter 2015 Financial Results and Provide Business Update on August 6, 2015 2Judge Pushes Back Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 2Judge Pushes Back Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 3
... 28 BioCis Pharma Ltd., a,privately-held drug development ... Phase I clinical testing of ProtoCure(TM) intravesical,instillation solution, ... is based on a new mechanism of action ... cancer growth and proliferation,locally. , ...
... a leader in the field of human gene therapy,announced ... Drug,Designation to AMT,s gene therapy product AMT-021 for the ... Orphan Drug Designation for AIP entitles AMT to ... AMT-021 if this,product candidate is the first new drug ...
Cached Medicine Technology:BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug 2AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria 2AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria 3
(Date:7/29/2015)... Baltimore, MD (PRWEB) , ... July 29, 2015 , ... ... to Get Checked for Skin Cancer ," discussed the importance of having regular skin ... if a person has excessive exposure to ultraviolet rays. When caught early, skin cancer ...
(Date:7/29/2015)... ... July 29, 2015 , ... Several years ago, in order ... with autism, Little City took a proactive stance and began planning the Children’s Village ... grant provides valuable support to building the third home. , “We are very pleased ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... Since the late 1970s, Dr. Cottrell has been making predictions about the economy, ... Earth, documents many of these prognostications. He warns that extreme weather conditions and ...
(Date:7/29/2015)... North Carolina (PRWEB) , ... July 29, 2015 ... ... MetLife, Inc ., a global provider of life insurance, annuities, employee benefits ... Team Challenge North Carolina inclusive sporting event taking place in Charlotte, North ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... is seeking funding for a study on the potentially lifesaving impact of removing ... today . , The research proposal is based on a successful pilot ...
Breaking Medicine News(10 mins):Health News:Get Checked for Skin Cancer Early and Often 2Health News:Get Checked for Skin Cancer Early and Often 3Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 2Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 3Health News:Author Warns Public to Prepare for Imminent Environmental Disaster 2Health News:MetLife Joins World T.E.A.M. Sports’ Adventure Team Challenge North Carolina as Presenting Sponsor 2Health News:MetLife Joins World T.E.A.M. Sports’ Adventure Team Challenge North Carolina as Presenting Sponsor 3Health News:Children's Medical Safety Research Institute Announces Innovative Study on Alzheimer’s Treatment Is Subject of Crowd Funding Campaign 2Health News:Children's Medical Safety Research Institute Announces Innovative Study on Alzheimer’s Treatment Is Subject of Crowd Funding Campaign 3
... good for heart health, at least among men, a ... researcher Robert Gramling, M.D., D.Sc., found that men who ... actually experienced a three times lower incidence of death ... not support the same conclusion among women. One possible ...
... Australian first, scientists at Sydney,s Centenary Institute have mapped ... has the potential to turn the way we discover ... time for new treatments. , "These membrane proteins are ... an increased,understanding of them is vital for future drug ...
... Theoretical Bioinformatics at the German Cancer Research Center (Deutsches ... how cells decide whether or not to migrate. Using ... molecular targets within a cell that have to be ... direction. This method may help to develop new treatments ...
... YORK and PARSIPPANY, N.J., July 14 Healthfirst ... a free online service,for electronic claims submissions. This ... medical providers to do business with the health ... faster exchange of,information, higher acceptance rates and quicker ...
... announced the appointment of Gregory Ciottone,MD to the position of Chief ... ... Company., LONGMONT, Colo., July 14 ... Ciottone, MD,to the position of Chief Medical Officer. Dr. Ciottone will ...
... Combat Lifesaver ... ... the summer of 2005, the,U.S. Army approached Recon Mountaineer(R) LLC ... the Combat Lifesaver program, and,at gaining their approval, the TC3(R) ...
Cached Medicine News:Health News:Positive thinking is prescription for the heart 2Health News:Discovery first step to new therapies 2Health News:Cellular decision on the computer 2Health News:Healthfirst and MD On-Line Partner to Streamline Claims Processing 2Health News:American Hospital Management Company Appoints Gregory Ciottone, MD as Chief Medical Officer 2Health News:American Hospital Management Company Appoints Gregory Ciottone, MD as Chief Medical Officer 3Health News:American Hospital Management Company Appoints Gregory Ciottone, MD as Chief Medical Officer 4Health News:American Hospital Management Company Appoints Gregory Ciottone, MD as Chief Medical Officer 5Health News:Creator of Recon Moutaineer's Tactical Combat Casualty Care Bag Praises Combat Lifesavers 2
For the quantitative determination of High Density Lipoprotein in serum. Available in liquid type. Polyethylene glycol (6000) precipitating reagent. Linearity: 200 mg/dl....
Ready to use liquid single reagent for automated chemistry analyzers. Linearity to 1000 mmol/L...
The Proteineer suite integrates powerful mass spectrometers with robotics and bioinformatics to deliver maximum productivity in high-throughput proteomics....
The ProteomeLab PA 800 resolves and quantifies proteins by their isoelectric point and molecular weight, generates high-resolution peptide maps and carbohydrate profiles and provides front-end separa...
Medicine Products: